SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,180,209.38070502. The last known price of Ethereum is 2,270.17304981 USD and is up 0.59 over the last 24 hours. It is currently trading on 14230 active market(s) with $5,193,092,001.43 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

A reported major Binance hack has become the dominant catalyst, raising concerns about exchange security and potential selling pressure across crypto, including Ethereum. Traders are split between viewing ETHs decline as a buying opportunity and warning that the breach and broader risk-off sentiment could bring further losses.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 636,822,022.65079832 with 590,150,211.79771733 in circulation. The last known price of Solana is 94.05303263 USD and is down -1.56 over the last 24 hours. It is currently trading on 1189 active market(s) with $1,556,044,818.54 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solanas pullback amid broader crypto weakness dominates discussion, with traders also voicing concern that the reported Binance security incident could undermine confidence across the market. Some view the decline as a buying-and-staking opportunity, while others point to bearish momentum and warn of further downside.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp tech-led selloff, fueled by weak Big Tech earnings and renewed doubts about the returns on heavy AI spending, has put QQQ in focus. Traders are split between expecting an oversold rebound and warning of further downside, while speculation about Iran talks and oil prices adds to the volatility.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY discussion centers on a volatile rebound after a sharp selloff, with traders linking the move to falling oil and hopes for progress in U.S.-Iran talks, including a possible reopening of the Strait of Hormuz. Some see a relief rally, while others doubt the reports and warn that midterm uncertainty and concerns about AI-related tech valuations could keep markets choppy.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Escalating U.S.-Iran tensions and reported attacks threatening oil flows through the Strait of Hormuz are driving attention to USO and keeping crude prices elevated. Traders are divided between expecting further supply disruption and higher oil prices, and betting that diplomatic progress or a ceasefire could quickly unwind the geopolitical risk premium.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming quarterly report is the dominant focus, with traders debating whether strong AI-driven growth and guidance can meet expectations already viewed as exceptionally high. Bulls anticipate another beat, while skeptics point to the stocks rich valuation and recent AI-sector weakness as risks if guidance disappoints or merely meets the bar.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

SOXX is drawing attention after a sharp semiconductor selloff, as investors question whether massive AI infrastructure spending will generate adequate returns; weak Intel guidance and broader tech selling added pressure. Traders are split between fears of an AI-trade unwind and expectations of a rebound, citing strong chip demand and oversold conditions.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to fresh 52-week highs ahead of Q3 earnings has drawn attention, with traders citing BRIUMVIs sales growth and bullish call-option activity. Buyout and short-squeeze theories are also prominent, but remain speculation rather than confirmed catalysts.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff ahead of its upcoming earnings report has traders focused on whether the ad-tech business can sustain growth amid concerns about the broader ad market, competition and analyst downgrades. Bulls argue the decline overlooks strong profitability and growth, while bears fear weaker results or guidance could deepen the downturn.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA accelerated approval of a competing treatment for recurrent respiratory papillomatosis has focused attention on the threat to Precigens PAPZIMEOS and contributed to a sharp after-hours selloff. Traders disagree on how much competition it poses: some see Inovios surgery-free regimen as an advantage, while others point to Precigens first-mover position, established sales, and full approval.

statis crypto Watchlist

Bitcoin

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?

GRI Bio, Inc. (GRI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GRI Bio Reports Positive Study Results For Chronic Lung Disease, But Stock Slumps 20% — What Happened?

Equity

The company said that the new data indicate that GRI-0621 may support the regeneration of lung tissue.

GRI Bio Drug Shows Promising Lung Function Recovery In Patients With Thickened Lungs

GRI Bio shared promising data from a Phase 2a trial for idiopathic pulmonary fibrosis, a chronic lung disease with no known cause.read more...

Barclays lifts Kojamo, I-RES ratings; cuts Grainger on low yield

This account has been verified as an official GRI representative.

Verified Account

GRI Bio

GRI Bio, Inc. engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.

GRI Bio Inc

Neutral Sentiment

<ul class="summary-bullets"><li>The latest findings include RNA-sequencing data showing that GRI-0621 significantly modulated genes associated with lung injury.</li><li>Prior Phase 2a results had already shown favorable safety and tolerability, as well as reduced disease progression.</li><li>Stocktwits users speculated that short selling could be the reason behind the stock’s decline.</li></ul>GRI Bio, Inc. (GRI), on Wednesday, announced encouraging new results from its Phase 2a study of GRI-0621 in patients with Idiopathic Pulmonary Fibrosis (IPF), a chronic and progressive lung disease.The latest findings include RNA-sequencing data showing that GRI-0621 significantly modulated genes associated with lung injury, myofibroblast activation, extracellular matrix deposition, fibrosis progression, and alveolar repair compared with placebo.<h2 class="st-heading-2">Treatment May Support Lung Tissue Regeneration</h2>Crucially, the new data indicate that GRI-0621 may support the regeneration of lung tissue, including the repair of the alveolar basement membrane and the&nbsp;transition of AT2 (Alveolar Type) epithelial cells to AT1, which are key steps in restoring lung function.Prior Phase 2a results had already shown favorable safety and tolerability, reduced disease progression, and improvements in exploratory endpoints, such as forced vital capacity, with twice as many treated patients maintaining lung function compared with standard care.“The data from the Phase 2a study exceed our expectations. The totality of data generated in this Phase 2a study suggests that GRI-0621 may represent a fundamentally different approach, with the potential to alter the trajectory of disease by promoting repair of damaged lung tissue,” said Marc Hertz, chief executive officer of GRI Bio.<h2 class="st-heading-2">Short Selling Speculation</h2>However, despite the seemingly positive development, <a href="https://stocktwits.com/symbol/GRI">GRI shares</a> fell 20%. But users remained bullish, despite what many speculated as short selling.<stembedurl>https://stocktwits.com/Tradebub/message/643136568</stembedurl><stembedurl>https://stocktwits.com/Kookoovia/message/643141732</stembedurl>Despite the sharp intra-day decline, retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier. GRI was also among the top trending tickers on the platform.<h2 class="st-heading-2">Reverse Split</h2>Last week, GRI Bio announced a 1-for-28 reverse stock split to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.The action became effective after-market hours on January 23, 2026, while trading on an ex-reverse split basis began on Monday. The split reduced outstanding shares from about 15 million to 536,000.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/sbux-stock-climbs-7-premarket-after-q1-results/cmyg421R40I">SBUX Stock Jumps 7% Today – US Transactions Grow For The First Time In Two Years</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ZoomInfo said net revenue retention was stable for the third consecutive quarter. 

SPDR Dow Jones Global Real Estate ETF

SPDR Dow Jones International Real Estate ETF

SPDR Portfolio Europe ETF

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.53
Prev Close	$1.57
Open	$1.59
Dividend Yield	0.00%
50-Day Moving Average	$1.82
Beta	1.29
Avg. Volume	560,462.69
PE Ratio	-0.03

52-Week High	$64.12
52-Week Low	$1.36
Market Capitalization	$3.34M
EPS (Annual)	-$121.80
Price to Book	0.33
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

GRI Fundamentals